BioCentury
ARTICLE | Company News

Ambrx, MabSpace deal

January 6, 2017 10:05 PM UTC

Ambrx and MabSpace partnered exclusively to discover and develop oncology antibody drug conjugates (ADCs). The partners will use MabSpace's humanized antibody technology in combination with Ambrx's EuCode conjugation platform. The partners said they will share costs and rights to resulting products in the global collaboration. MabSpace said the deal includes an option to renegotiate once development costs become "significant, e.g., Phase III." ...